Podcasts about Paiva

Celebração à noite | 26 de outubro de 2025.Venha ser comunidade da Fé e da Vida com a gente!

Discurso: Secretário Eleuses Paiva (Saúde) | Inauguração do Novo Hospital e Maternidade Santa Ana e Aniversário de 445 anos de História da Cidade Santana de Parnaíba by Governo do Estado de São Paulo

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Há diferentes níveis de relacionamento com Ele — as multidões que buscam milagres, os discípulos que seguem para aprender e os íntimos que conhecem o coração do Mestre. Deus não faz distinção de filhos, mas há filhos que preferem estar mais perto. A intimidade é o lugar onde a fé amadurece, a voz de Deus se torna mais clara e os milagres acontecem em silêncio.Jesus não chamou pessoas perfeitas, mas corações rendidos. Ele continua convidando cada um de nós a subir o monte, a deixar o barulho da multidão e ouvir o sussurro da Sua voz. A proximidade muda tudo — transforma curiosos em discípulos e discípulos em amigos. Mais do que estar perto do poder de Deus, somos chamados a estar perto da Sua presença.Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Discurso: Eleuses Paiva, Secretário da Saúde | Anúncio de Repasse de Recursos Fundo a Fundo para a Saúde dos Municípios Paulistas by Governo do Estado de São Paulo

Neste episódio, somos convidados a viver o caminho da confiança como uma jornada de rendição, não de controle. Líderes que estão sendo formados por Deus em lugares ocultos, moldados em desertos e fortalecidos no silêncio, aprendendo que o propósito não começa quando entendemos, mas quando nos entregamos. Confiar é se lançar nos braços do Pai, mesmo sem entender o caminho, e descobrir que o silêncio d'Ele não é ausência, mas direção.Deus está levantando uma geração que não vive baseada em cálculos, mas em fé. Pessoas que soltam o volante e deixam Deus conduzir. A confiança é a ponte entre o caos e a promessa, e nesse lugar de entrega, até desvios se tornam destino. Quando o controle termina, o propósito começa.Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Laura Müller é psicóloga, sexóloga, palestrante, autora e jornalista, conhecida nacionalmente por sua participação no programa Altas Horas, da TV Globo, ela é destaque quando o assunto é sexualidade e autoconhecimento. Atualmente Laura produz conteúdo voltado à saúde sexual e bem-estar para as redes sociais e realiza atendimentos individuais e para casais em seu consultório online.

Coletiva: Gov Tarcísio de Freitas e Sec Eleuses Paiva (Saúde) | Inauguração de novas Instalações do Hospital Lucy Montoro em Rio Preto - 22.10.2025 by Governo do Estado de São Paulo

Discurso: Sec. Eleuses Paiva (Saúde) | Inauguração do Hospital Regional São Pedro em Mirassol - 23.10.2025 by Governo do Estado de São Paulo

Mesmo quando tudo parece fora do lugar e caos, o som que você ouve não é guerra, é reforma. O Carpinteiro da Galileia está reconstruindo o que o inferno tentou destruir. Deus não te tira da casa pra te consertar, Ele reforma com você dentro.Se está bagunçado, não desanime! É o Céu martelando algo novo dentro de você. O mesmo Jesus que foi carpinteiro em Nazaré é o arquiteto da tua reconstrução.Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Verifique, o Que Você Tem? | Pra. Léia Paiva | 05/10/25

Discurso: sec. Eleuses Paiva (Saúde) | Entrega de Novos Leitos do Instituto Dante Pazzanese de Cardiologia - 16.10.2025 by Governo do Estado de São Paulo

Recorded 10/13/25 at the Kaho'olawe Island Reserve Commission government office in Wailuku  The goal of the Hui Mo‘olelo program is to capture an authentic moment of connection through stories that are embedded in a Hawai‘i sense of place. As participants complete our immersive storytelling workshop, each identify a partner to engage in an audio-recorded talk-story that captures these connective moments. These recordings become the basis for annual requests for proposals to interpret as a work of public art in collaboration with community members. Proposals are selected by a community panel, followed by an intensive learning and cultural exchange that is rooted in specific places throughout Maui County. Representing a wide range of special places and stories, the collection is available for your research, enjoyment, memory or inspiration at https://www.mauipublicart.org/hui-moolelo.html.

Nesta série somos convidados a voltar à mesa com o Rei, um lugar de comunhão, restauração e presença!Há poder em retornar ao lugar da intimidade com Deus, o valor da família, a importância de reconhecer o chamado e cuidar da própria casa antes de servir aos outros. É um convite para parar, ouvir a voz de Deus e sentar-se à mesa onde Ele restaura identidades, cura feridas e renova propósitos.Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

No episódio desta semana do 24Cast, Romualdo Silva recebe Carla de Paiva, da VIASOFT, para falar sobre um tema essencial e muitas vezes esquecido: o papel do suporte interno no sucesso do uso do Bitrix24 e de qualquer CRM. Carla compartilha sua experiência como vendedora, implementadora e agora Sales Ops, mostrando como a presença de um profissional interno dedicado ao sistema faz toda a diferença nos resultados da empresa. Eles também conversam sobre: - Boas práticas na gestão e atualização do CRM - A importância da governança e da documentação de processos - Como o Bitrix24 evoluiu e o papel das novas funções comerciais, como Sales Ops e Sales Enablement - A parceria entre consultoria e empresa no uso estratégico do Bitrix24 Se sua empresa quer tirar o máximo do CRM, esse episódio é para você. Escute, comente e compartilhe. Não esqueça de deixar 5 estrelas: 

Sonora: Eleuses Paiva - Governo de São Paulo disponibiliza 2.500 ampolas de antídoto contra metanol para abastecer serviços de saúde by Governo do Estado de São Paulo

Chamamos o domingo de sagrado e, a partir de segunda, costumamos dizer que vamos viver nossa vida “secular”. Contudo, no Éden, não havia separação de sagrado e secular, nós que criamos essa separação.Precisamos ser ministros de tempo integral, adoradores de tempo integral, seja na igreja, seja no nosso trabalho, nos estudos, ou em qualquer papel que temos desempenhado. Onde estivermos devemos levantar um altar de adoração e fazer tudo para a glória do Senhor!Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Confira na edição de Os Pingos nos Is desta sexta-feira (26):O presidente dos Estados Unidos, Donald Trump, pode visitar o ex-presidente Jair Bolsonaro (PL-RJ) no Brasil. A articulação estaria sendo conduzida pelo deputado federal Eduardo Bolsonaro (PL-SP) e é vista como um forte aceno político após a condenação de Bolsonaro no STF.Familiares e aliados próximos do ex-presidente afirmam que ele está cercado de “aproveitadores”. O desabafo ocorre em meio ao racha na direita, marcado por críticas a parlamentares que utilizam a imagem de Bolsonaro para fins eleitorais.Trump também avalia revogar o visto de Tomás Paiva, comandante do Exército brasileiro, apontado como aliado de ministros do STF. A medida é interpretada como uma nova rodada de sanções contra autoridades brasileiras e amplia a pressão sobre o Judiciário e as Forças Armadas.Você confere essas e outras notícias na edição de Os Pingos nos Is.

Are you really investing in yourself? ....the way you invest in your career, your family, your future?In this episode of Overflow with Kimberly Snider, please welcome Fatima Pavia Lusito, a seasoned HR consultant, leadership coach, and founder of Fatima Lifestyle Living & Coaching. With over 25 years of experience guiding leaders and individuals through growth, performance, and change, Fatima shares her empowering path (beyond burnout!) . . . and offers a wealth of wisdom (and a nudge!) to prioritize YOU.

Originalmente exibido em 24.02.2025. O Bate Papo na Saúde desta edição fala sobre Proibição de Celulares nas Escolas. O benefício da medida é praticamente um consenso e ela foi comemorada pela imensa maioria de pais e educadores. Para compreender melhor o assunto, o apresentador Renato Farias conversa com o doutor em Psicologia Social e especialista em Educação Digital do Instituto Alana, Rodrigo Nejm e com a coordenadora adjunta do Grupo de Atuação sobre Criminalidade Cibernética do Ministério Público Federal (MPF), Neide Cardoso de Oliveira. // CRÉDITOS apresentação e roteiro Renato Farias// produção Christóvão Paiva// edição Pablo French//diretor de imagem Ben-Hur Machado// diretor de fotografia Tota Paiva//cinegrafistas Seblen Mantovani André Luiz e Tota Paiva//tecnico e som Raphael Brendt//figurino Roberta Ferreira//controller Luiz Henrique Ribeiro//ass.de produção Philipe Mandrani//Motion designer Jefferson Arcanjo//direção geral Rodrigo Ponichi//coordenação de conteúdo Yasmine Saboya// coordenação de produção Luciana Souza//coordenação de produção Plano Geral Filmes Paulo Lontra//coordenação técnica Ben-Hur Machado// coordenação de finalização Pablo French// produção Plano Geral Filmes//Realização Canal Saúde***E-mail: canalsaude.podcasts@fiocruz.brNão deixe de acompanhar as redes sociais do Canal Saúde.Twitter: twitter.com/canalsaudeInstagram: instagram.com/canalsaudeoficialFacebook: facebook.com/canalsaudeoficialYouTube: youtube.com/canalsaudeoficialO Canal Saúde Podcasts reúne alguns programas do Canal Saúde produzidos para televisão, que ganharam sua versão apenas em áudio. Equipe: Gustavo Audi / Valéria Mauro / Marcelo Louro

Juliana Paiva, gerente de Estudos e Pesquisas Sociais do IBGE, falou no Direto ao Ponto sobre o início de uma pesquisa inédita sobre enchentes, que contemplará o Vale do Rio Pardo.

Juliana Paiva, gerente de Estudos e Pesquisas Sociais do IBGE, falou no Direto ao Ponto sobre o início de uma pesquisa inédita sobre enchentes, que contemplará o Vale do Rio Pardo.

A mulher do vaso de alabastro derramou tudo diante de Jesus, e o que para muitos parecia desperdício, para ela era adoração. Sua fome rompeu protocolos e se tornou memória eterna.A fome verdadeira nos leva a entrega total. Enquanto Judas trocou Jesus por moedas, aquela mulher entregou tudo a Ele. Que a nossa fome seja sempre pela presença, e não pelo que é passageiro.Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Sansão: alguém separado por Deus, mas que se perdeu por não guardar os limites da santidade. Mesmo assim, a graça de Deus mostrou que sempre há recomeço.Santidade não é perder liberdade, é proteger o propósito. A verdadeira força não está nos braços, mas nos joelhos dobrados diante de Deus.Para escutar toda a palavra fique aqui conosco ou assista pelo YouTube. Você consegue nos encontrar em todas as redes sociais por ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iirbrasil⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

No NerdCast de hoje, Alexandre Ottoni, Carlos Voltor, Leo Lopes, Marcelo Bassoli e Tucano jogam Adedanha (Adedonha, Stop ou o que preferir) e defendem os melhores de cada tema com a letra escolhida!!! BEM BRASIL Conheça as Batatas Bem Brasil, a batata do NerdCast 1000: https://jovemnerd.short.gy/Bem_Brasil_NC1K_NerdCast LIVES JOVEM NERD Acompanhe as lives oficiais do Jovem Nerd na Kick: https://jovemnerd.short.gy/Kick_Jovem_Nerd_NerdCast LUIZA LABS Inscreva-se no Programa de Treinee IA Magalu: https://jovemnerd.short.gy/Treinee_Magalu_NerdCast Siga o Instagram do Luiza Labs: https://jovemnerd.short.gy/Luiza_Labs_Instagram_NerdCast Veja a página de carreiras do Luiza Labs: https://jovemnerd.short.gy/Luiza_Labs_Pagina_Carreiras_NerdCast PEDIDOS DE DOAÇÃO Pedido de doação de sangue de qualquer tipo para José Maria Batista de Paiva. Qualquer tipo sanguíneo. Local: INCA 1 – Praça da Cruz Vermelha, 23, 2º andar E-MAILS Mande suas críticas, elogios, sugestões e caneladas para nerdcast@jovemnerd.com.br APP JOVEM NERD: Google Play Store | Apple App Store ARTE DA VITRINE: Randall Random Baixe a versão Wallpaper da vitrine EDIÇÃO COMPLETA POR RADIOFOBIA PODCAST E MULTIMÍDIA CONFIRA OS OUTROS CANAIS DO JOVEM NERD Learn more about your ad choices. Visit megaphone.fm/adchoices

Antigo autarca de Castelo de Paiva avisa que todos os responsáveis sabiam qual o estado da ponte de Entre os Rios. Paulo Ramalheira Teixeira acusa antigo executivo de falta de vontade política.See omnystudio.com/listener for privacy information.

Produção acelerada, máquinas cada vez mais inteligentes... mas nossas horas de trabalho só aumentam. Onde está o ganho?

Worrying is never much fun, but it's especially not fun in the leadup to a performance or audition. And even more so when we get stuck in a “worry loop” and can't seem to get ourselves out of it.It's a little like the time my family visited Paris when I was a kid, and my dad got stuck in the roundabout around the Arc de Triomphe. I don't know how long we drove around and around, but I do know that I fell asleep at some point, and when I woke up, we were still looping around.

Em 2025, a polêmica história de Margarida Bonetti (acusada de manter Hilda em condições análogas à escravidão por 20 anos nos EUA) ganha nova dimensão com a série documental do Prime Video. Erika Miranda conversa com Chico Felitti (criador do podcast original), Katia Lund (diretora) e Mariana Paiva (roteirista) sobre bastidores, novas descobertas, documentos inéditos do FBI, e como foi transformar o caso que chocou o Brasil em uma produção audiovisual.Instagram: @erikamirandas e @casosreaisoficial

Teresa Paiva é médica neurologista e a maior referência portuguesa em medicina do sono. É doutorada em Neurologia e, para além de uma vastíssima investigação científica nesta área, tem também prática clínica, no CENC — Centro de Medicina do Sono, onde é diretora clínica. Falámos a propósito do seu livro mais recente, ‘O Meu Sono e Eu — Mitos e Factos‘, publicado este ano pela Livros Horizonte. _______________ Índice (com timestamps): (0:00) Introdução (4:40) Porque dormem os seres-vivos? Como dormem os lagartos? E os polvos? Sono bifásico na Idade Média (19:58) Ritmo circadiano e cronotipos | É verdade que há diferentes cronotipos? | Desafios de ser noctívago | Cronotipo vs atraso de fase | A importância da exposição à luz solar. (33:56) Sesta — como fazer? | Quais são os processos biológicos no corpo que regulam o sono? (41:14) Que erros andamos a cometer que nos fazem dormir mal? | Porque dormimos menos que os chimpanzés? | É possível recuperar sono perdido? (46:04) O Mundo de hoje vive numa epidemia de falta de sono — particularmente em Portugal? | ‘Sleep patterns in Portugal’, tese de Cátia Reis | Estudo impacto da falta de sono no PIB | consequências concretas (pedir estudo e enviar o outro) | Ou será que dormimos menos mas melhor do que antigamente? (57:09) Fases do sono: REM e não-REM? | Pintainhos sono REM | Porque sonho mais nas férias? | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839702/ (1:11:42) Para que servem os sonhos? | Apesar das diferenças culturais e individuais, temos todos sonhos parecidos | Porque nos esquecemos dos sonhos? (1:15:20) “Sleep hacks” — algum vale a pena? | Suplementos? Benzodiazepina (Xanax) | Neuromodulação não invasiva como terapia para a insónia (1:28:37) Doenças do sono: insónias, apneias, doenças do movimento, sonambulismo, terrores noturnos, epilepsia, transtornos do sono REM, alterações circadianas. _______________ O acto de dormir é tão essencial quanto comer ou respirar, e, no entanto, tantas vezes o subestimamos ou relegamos para segundo plano nas nossas vidas agitadas. Quem nunca disse: “Dormirei quando estiver morto”? Mas a verdade é que o sono é fundamental para a nossa saúde física e mental e é um dos pilares do nosso bem-estar. Talvez até alguns de vocês, ao ouvirem este episódio, estejam a pensar em quantas horas de sono conseguiram na noite anterior ou quantas gostariam de ter tido. Para nos ajudar a compreender melhor a Ciência do Sono, convidei a médica Teresa Paiva, a grande referência portuguesa na medicina do sono (e alguém que, como digo na introdução, há muito queria trazer ao 45 Graus). A convidada tem uma vastíssima investigação nesta área e uma extensa prática clínica. Falámos a propósito do seu livro mais recente, ‘O Meu Sono e Eu — Mitos e Factos’. Na nossa conversa, começámos pela intrigante questão de por que dormem os seres vivos, incluindo animais tão distantes de nós evolutivamente, como os polvos; e mergulhámos nos ritmos circadianos, incluindo o estranho hábito medieval de dormir dois sonos, acordando de madrugada para voltar a deitar-se umas horas depois, e os desafios – estes contemporâneos – de ser um noctívago num mundo dominado pelos matutinos. Exploramos também os prós e contras da sesta e os erros mais comuns que cometemos, e que comprometem a quantidade e a qualidade do nosso sono. Ou será que a maior causa da nossa falta de sono não somos nós, mas antes um problema maior, estrutural dos tempos actuais: uma “epidemia” de falta de sono causada pelo acelerar da economia e pela overdose de estímulos? As estatísticas sugerem que isto é uma realidade, no Mundo desenvolvido e particularmente em Portugal. A convidada defende esta tese, e certamente que no mundo ideal a maioria de nós dormiria mais horas por noite. Mas tentei também fazer um pouco de advogado do diabo em relação a este tema (como já estão habituados no 45 Graus). Sendo o sono uma necessidade tão básica, fico com algumas dúvidas se é possível uma privação de sono tão sistémica. De seguida, voltando à ciência do sono propriamente dita, desvendámos os mistérios das fases do sono e o fascinante mundo dos sonhos. E para aqueles que procuram formas de otimizar o sono, perguntei à convidada a sua opinião sobre os populares ‘sleep hacks’ e até que ponto eles realmente funcionam. See omnystudio.com/listener for privacy information.

O que a experiência de ter filhos revela para mães e pais hoje? Este episódio reúne Marcelo Rubens Paiva e Martha Nowill, autores de romances que buscam respostas para essa pergunta entrelaçando paternidade, maternidade e dilemas contemporâneos. Enquanto a atriz relata a experiência de se descobrir grávida de gêmeos aos quarenta anos e em plena pandemia no seu livro Coisas Importantes Também Serão Esquecidas (Companhia das Letras), Paiva alterna memórias de infância e sua própria experiência como pai em O Novo Agora (Alfaguara), que completa a trilogia composta ainda por Feliz Ano Velho (1982) e Ainda Estou Aqui (2015). A conversa teve mediação da jornalista Micheline Alves, roteirista do programa Conversa com Bial, e aconteceu durante A Feira do Livro 2025.    O episódio foi realizado com apoio do Ministério da Cultura e tem apresentação exclusiva da Petrobras. Seja um Ouvinte Entusiasta e apoie o 451 MHz: https://bit.ly/Assine451  

Depois de quatro meses, 23 jogos e um aproveitamento de 56,5% à frente do Botafogo, Renato Paiva não resistiu à eliminação diante do Palmeiras, nas oitavas de final da Copa do Mundo de Clubes. O que causou a queda de Paiva? Postura em campo? Problemas com o elenco? Insatisfação de Textor com as escalações? Rafa Barros, Bárbara Mendonça e Pedro Dep analisam o trabalho do português. E você, concordou com a saída dele? DÁ O PLAY!

For today's episode Aaron talks to crypto tax lawyer Daniel de Paiva Gomes about the sweeping changes proposed by Brazil's Ministry of Finance earlier this month. We explored the changes to the IOF financial transactions tax and the relevant implications, as well as the provisional measure released by the Ministry of Finance seeks to overhaul tax treatment of crypto assets in the country.You can connect with Daniel on Linkedin____________________________________________________________Brazil Crypto Report is presented by AveniaIf you're building a wallet, a crypto consumer app, or a global payment platform, Avenia is your bridge to Latin America. Instantly connect to PIX, SPEI, and CBU using stablecoins — with one API. No banks. No FX desks. No SWIFT. Move money globally, with full compliance and real-time settlement. Learn more at avenia.io.------------------------------------------------------------------

Geração de Onesíforo | Pr. Jetro Paiva | 28/07/24

A Orfandade de Moisés | Pr. Jetro Paiva | 28/07/24

Comediante, Atriz, dubladora, dona do Vênus podcast e dos nossos corações. Criss Paiva é a professora, que ensina como aproveitar a vida.Sotaque, presença e um humor único! Júnior Chicó conquistou o público com suas piadas inteligentes e afiadas, ele nunca economiza nos absurdos do dia a dia e você facilmente vira fã!

Hosted by Andrew Quinn and Darren Mooney, this week with special guest Ingrid Machado, The 250 is a (mostly) weekly trip through some of the best (and worst) movies ever made, as voted for by Internet Movie Database Users. New episodes are released every second Saturday at 6pm GMT, with the occasional bonus episode between them. This week, Walter Salles' Ainda Estou Aqui. In 1970s Brazil, the Paiva family lives a charmed and tranquil existence. As the country around them slips into dictatorship, the family has managed to hold on to something close to normality. However, that peaceful life is suddenly and brutally shattered as the outside world comes crashing in. At time of recording, it was ranked 228th on the list of the best movies of all time on the Internet Movie Database.

Vitória e classificação sobre La U tem as marcas da superação e da maturidade, numa noite mágica do camisa 99. Como a expulsão de Jair reacendeu a chama de um grupo resiliente, determinado e competitivo para, novamente com 10 jogadores, dividir com a torcida os méritos da vitória mais marcante do ano? Como projetar as oitavas de final? O que Paiva e o Botafogo podem conquistar na temporada? DÁ O PLAY!

You “kinda” don't want to miss this week's episode of Hey Sis, Eat This, as we welcome special guests Julie Paiva, a talented screenwriter known for Kinda Pregnant, now airing on Netflix, and her wonderful sister Lisa. Together, they share a heartfelt and humorous look at their unconventional childhood in Northern California, celebrating the life lessons and creativity imparted by their remarkable mother, Momma Bibi. We rewind to the ‘80s, when Momma Bibi and Dad Michael divorced when the sisters were seven and ten. Bibi chose stability first when co-parenting, keeping her girls in their childhood home with their dad, while still fostering a close relationship with them through foodie filled adventures. Daddy Michael tackled single-parent mode with “French-Toast Thursdays,” microwave-cooking classes, and a very liberal kitchen-only cigarette policy that cured any teen smoking phase fast . A Sufi seeker who swaps small talk for theories on the nature of time, Momma Bibi raised her daughters on spiritual “square dancing” and Cheez Whiz with jarred beef on annual camping trips. Her trademark Bibi-isms (“blow your nose, get a little glass of orange juice, take two sips then tell me what happened”) still echo whenever life gets wobbly . Tune in to hear how Bibi instilled in her daughters the importance of love, peace, and connection, and how she encouraged them to embrace their individuality and celebrate their own unique paths. Also, make sure to check out Julie's hit movie, Kinda Pregnant, starring Amy Schumer, now playing on Netflix and her next venture, a children's book series launching with The Lucky Penny, inspired by Momma Bibi's DIY optimism. Everything Julie Paiva Kinda Pregnant - Now playing on Netflix Julie on Instagram: @julieannepaiva What you'll hear: What we've been cookin', who we've been entertainin', and any kitchen conundrums of the week... often in our Momma's Texas accent Chatting with siblings about what it was like around their dinner table growing up, favorite family recipes and stories that celebrate moms Interviews with celebrity chefs, restaurateurs, and culinary entrepreneurs about the influence and inspiration from their moms Weekly recipes from us and our guests posted out the Hey Sis, Eat This website - Website: https://www.heysiseatthis.com   - Recipes from our Us and Our Guests: https://www.heysiseatthis.com/our-recipes  - Call into the Hey Sis Hotline: 1-866-4 HEY SIS or 1-866-443-9747 - Email: hello@heysiseatthis.com   - Instagram: https://www.instagram.com/heysiseatthis/  - Facebook: https://www.facebook.com/heysiseatthis  - YouTube: https://www.youtube.com/@heysiseatthis 

We return to international cinema with 2024's Oscar winner for Best International Film, "I'm Still Here," a powerful true story about Brazil's military dictatorship and one family's devastating experience.• Based on the true story of Eunice Paiva, whose husband disappeared during Brazil's military dictatorship in 1971• Features an extraordinary performance from Fernanda Torres that captures the quiet strength of a mother protecting her children while seeking answers• Set against the backdrop of Rio's beaches, the film contrasts the family's idyllic lifestyle with the ever-present military threat• Director Walter Salles uses authentic period filmmaking techniques including Super 8 footage to create an immersive historical experience• Portrays the difficult reality of living under authoritarian rule with subtle tension and emotional restraint• Shows how Eunice transformed her personal tragedy into purpose by becoming a lawyer and human rights advocate• Received universal critical acclaim with a 97% rating on Rotten Tomatoes from both critics and audiencesLetterbox'd Synopsis: In 1971, military dictatorship in Brazil reaches its height. The Paiva family — Rubens, Eunice, and their five children — live in a beachside house in Rio, open to all their friends. One day, Rubens is taken for questioning and does not return.

Na décima edição da sétima temporada do podcast Na Ponta dos Dedos, Rafael Lopes recebe Fernando Paiva, ex-engenheiro de Fórmula 1 e que trabalha atualmente com marketing esportivo, para ouvir histórias sobre a categoria. Além disso, a prévia do GP da Emilia-Romagna, em Imola. Por fim, um papo com Beto Monteiro, vencedor da corrida 1 da etapa de Londrina e bicampeão da Copa Truck.

Warren Buffett, o maior investidor da história do planeta, subiu ao palco da Bershire Hathaway Shareholders Annual Meeting por 60 vezes, mas talvez essa tenha sido sua última participação. As especulações estavam certas: o Oráculo de Omaha anunciou sua aposentadoria no fim de 2025.Nós estávamos lá, após anos de cobertura do evento, dessa vez tivemos a mais completa no local. Os brasileiros marcaram presença, inclusive nomes relevantes do mercado, como Cesar Paiva, fundador e gestor da Real Investor, um dos melhores fundos de ações do Brasil.Aproveitamos o momento para realizarmos um resumo dos grandes pontos das falas de Buffett e dos aprendizados que tivemos durante a conferência. Sob a perspectiva de quem inspirou sua carreira na filosofia propagada pela estratégia regida a décadas pela Berkshire. Aperta o play!

Gustavo Mioto, é um cantor, compositor e multi-instrumentista brasileiro. Iniciou carreira em 2012 com seu álbum de estreia Fora de Moda.Hoje é um dos maiores nomes da música sertaneja.

Welcome to The Legacy Warriors Podcast! Highlighting and breaking down the two best feeder leagues to the big show, LFA and Cage Warriors. THIS PATREON IS FOR THE FIGHT LINK DATABASE, NOT MY PICKS/BETS/WRITE UPS.

We're still here discussing Walter Salles unsettling Oscar nominated retelling of the Paiva family and their life under Brazil's military dictatorship. If you're enjoying the show, consider buying us a coffee, sending us an email or hitting us up on Twitter(X), BlueSky or Instagram!You can catch our episodes early and ad free over on Nebula! Sign up with the link below. It really helps out the pod so we thank you in advance!https://go.nebula.tv/theonlypodcastaboutmoviesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

O filme brasileiro dirigido por Walter Salles e estrelado por Fernanda Torres e Selton Mello chega à cerimônia do Oscar, no próximo domingo (3), na disputa por três estatuetas: Melhor Filme, Melhor Filme Internacional e Melhor Atriz. Uma produção original Globoplay, Ainda Estou Aqui é resultado de 7 anos de trabalho e 4 meses de filmagem, com 547 profissionais envolvidos. Neste episódio especial, às vésperas da maior premiação do cinema, Julia Duailibi conversa com quatro integrantes da equipe que, por trás das câmeras, ajudaram a contar a história de Eunice Paiva e de sua família. Roteiristas premiados em Veneza, Murilo Hauser e Heitor Lorega relatam como foi transpor para o longa metragem uma violência que parecia escondida e que vai “entrando aos poucos” na casa e na vida da família Paiva. Eles falam sobre como foi acompanhar todo o processo de produção e observar de perto a construção das complexidades de Eunice Paiva por Fernanda Torres. Direto de Los Angeles, a dupla fala também sobre a expectativa para o Oscar. Claudia Kopke, figurinista, detalha como foi a busca pelas roupas para o filme, que se passa no início dos anos 1970. "Muita coisa era de acervo, porque dá mais verdade, já vem envelhecido", conta. Adrian Teijido, diretor de fotografia, explica como as memórias de Walter Salles ajudaram a compor a atmosfera visual do longa. "Era um desejo do Walter de que a primeira fase do filme fosse bastante solar, que a casa fosse alegre e cheia de amigos”, diz. Ele fala ainda sobre a escolha de gravar de maneira analógica e como essa opção ajudou a construir a atmosfera de um filme que já recebeu mais de 30 prêmios ao redor do mundo.